About: Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 November 1999

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 1999 (uk) article scientifique publié en 1999 (fr) im November 1999 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 November 1999 (en) artículu científicu espublizáu en payares de 1999 (ast)
publication date	wds:Q73165839-4EF416E2-AA4B-45D8-99BE-30126812973E
publication date	1999-11-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q73165839-103F702E-1BE1-4A12-BEBE-B3690F32E149 wds:Q73165839-38ED6385-D3AE-4B79-83A7-87D9E428776F wds:Q73165839-47181BC6-AA79-404B-B017-66A9DD90154A wds:Q73165839-5C427F20-33D2-4424-9743-B91DFF717C4D wds:Q73165839-65CEAA47-1F9D-44C0-AD61-151F40B36F93 wds:Q73165839-6E751764-1066-40F5-A1F7-B64A73440480 wds:Q73165839-7C955311-C0BA-4202-904F-772AA5E118F6 wds:Q73165839-90E1FEA6-4CB0-41A1-8F14-385635908C2C wds:Q73165839-B46F21F5-CFCC-4EAA-B6A3-A1B444D6A9C3 wds:Q73165839-C7877DC6-A268-4206-AD3E-7BFDE6A1F6CA wds:Q73165839-E679E3A9-3121-4050-8FAC-419FF8F36F9E wds:Q73165839-F424E62B-26E8-4EA8-A7C8-A6DAC144B190
author name string	Keller M Cohen S Zizic TM Sewell KL Wallach S Levy RM Lukert BP Greenwald M Chines AA Axelrod DW Boling E Emkey RD
rdfs:label	Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (en) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (nl)
skos:prefLabel	Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (en) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (nl)
name	Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (en) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (nl)
title	wds:Q73165839-06D6ECD7-ACE5-469F-A4B7-9418D662BD97
title	Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (en)
page(s)	wds:Q73165839-BD5DD600-A1CD-4E72-B074-35C7F5F337BC
page(s)	2309-2318
instance of	wds:Q73165839-A9116B40-E21C-4500-B633-13364ED1BB52
instance of	scholarly article
main subject	wds:Q73165839-DAABA608-854F-450F-8D30-AE75C073E310
main subject	placebo
PubMed ID	wds:Q73165839-4DA2D56A-1740-4FDE-80A0-1982B1B4973B
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10555025
PubMed ID	10555025
published in	wds:Q73165839-84C994D8-9674-4962-9C74-65D4122DA8D5
published in	Arthritis and Rheumatism
issue	wds:Q73165839-196BED35-16E2-4631-B816-665F23B26905
volume	wds:Q73165839-9DE41345-B57A-4339-993D-8B380408C120
issue	11
volume	42
DOI	wds:Q73165839-E54CE2C0-3D9C-4D6E-AAB4-B5BBE604FE00
DOI	http://dx.doi.org/10.1002/1529-0131(199911)42:11%3C2309::AID-ANR8%3E3.0.CO;2-K
DOI	10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73165839
is cites work of	Glucocorticoid-induced osteoporosis - a disorder of mesenchymal stromal cells? Drug insight: Existing and emerging therapies for osteoporosis A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis Targeted treatment in COPD: a multi-system approach for a multi-system disease Extraintestinal manifestations and complications in inflammatory bowel diseases Premenopausal bone health assessment 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Glucocorticoid-induced osteoporosis: pathophysiology and therapy Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate Co-morbidity in rheumatoid arthritis The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids. Reproducibility of bone mineral density measurement in daily practice Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club Hospital admissions and mortality in patients with COPD exacerbations and vertebral body compression fractures Glucocorticoid-induced osteoporosis Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge Prevalence and predictors of fragility fractures in systemic lupus erythematosus Risk factors for vertebral fracture in menopausal or postmenopausal Japanese women with rheumatoid arthritis: a cross-sectional and longitudinal study. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Glucocorticoid use in rheumatoid arthritis Practice patterns in patients at risk for glucocorticoid-induced osteoporosis Prevention and treatment of corticosteroid-induced osteoporosis Antiresorptive therapies for osteoporosis: a clinical overview Tolerability and compliance with risedronate in clinical practice The role of bone biopsy in patients with chronic renal failure Treatment of osteoporosis in chronic kidney disease and end-stage renal disease Bisphosphonates and atrial fibrillation: systematic review and meta-analysis Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences Management of glucocorticoid-induced osteoporosis Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice Time Related Changes of Mineral and Collagen and Their Roles in Cortical Bone Mechanics of Ovariectomized Rabbits Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates Medical treatment of vertebral osteoporosis Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software